Efficacy of galcanezumab in migraine central sensitization
Abstract Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide pathway (CGRP mAb), acts peripherally due to its large size. However, recent studies have suggested that CGRP mAbs may also have a central mode of action. This study aimed to evaluate the central effects of ga...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Portfolio
2024-09-01
|
| Saila: | Scientific Reports |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1038/s41598-024-72282-6 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|